Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant

Veterinary Research

Volumn 42, Issue 1, 2011, Pages

  Soboll Hussey, Gisela ^a   Hussey, Stephen B ^a   Wagner, Bettina ^b   Horohov, David W ^c   Van De Walle, Gerlinde R ^d   Osterrieder, Nikolaus ^e   Goehring, Lutz S ^a   Rao, Sangeeta ^a   Lunn, David P ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b Cornell University ^*  (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d GHENT UNIVERSITY   (Belgium)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EQUID HERPESVIRUS 1; EQUIDAE; HUMAN HERPESVIRUS 1;

CYTOKINE; MESSENGER RNA; VIRUS ANTIBODY; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUINE HERPES VIRUS; FEMALE; GENETICS; HERPES VIRUS INFECTION; HORSE; HORSE DISEASE; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; NOSE MUCOSA; RANDOMIZATION; VIREMIA; VIROLOGY; VIRUS SHEDDING;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HORSE DISEASES; HORSES; IMMUNITY, INNATE; MALE; NASAL MUCOSA; RANDOM ALLOCATION; RNA, MESSENGER; VIRAL PROTEINS; VIREMIA; VIRUS SHEDDING;

EID: 80051990283     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-42-23     Document Type: Article

References (41)

1. Equid herpesvirus 1 and equid herpesvirus 4 infections. Allen GP, Kydd JH, Slater JD, Smith KC, Infectious Diseases of Livestock Newmarket: Oxford University Press, Coetzer JAWT, RC, 1 2004 2 829 859
2. Pre-infection frequencies of equine herpesvirus-1 specific, cytotoxic T lymphocytes correlate with protection against abortion following experimental infection of pregnant mares. Kydd JH, Wattrang E, Hannant D, Vet Immunol Immunopathol 2003 96 3-4 207 217 10.1016/j.vetimm.2003.08.004 14592733 (Pubitemid 37330001)
3. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Soboll G, Horohov DW, Aldridge BM, Olsen CW, McGregor MW, Drape RJ, Macklin MD, Swain WF, Lunn DP, Vet Immunol Immunopathol 2003 94 1-2 47 62 10.1016/S0165-2427(03)00060-6 12842611 (Pubitemid 36808786)
4. Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses. Allen GP, Am J Vet Res 2008 69 12 1595 10.2460/ajvr.69.12.1595 19046006
5. Regulation of adaptive immunity by the innate immune system. Iwasaki A, Medzhitov R, Science 2010 327 5963 291 295 10.1126/science.1183021 20075244
6. Alphaherpesviruses and chemokines: pas de deux not yet brought to perfection. Van de Walle GR, Jarosinski KW, Osterrieder N, J Virol 2008 82 13 6090 6097 10.1128/JVI.00098-08 18385255 (Pubitemid 351875091)
7. Peptide transport activity of the transporter associated with antigen processing (TAP) is inhibited by an early protein of equine herpesvirus-1. Ambagala APN, Gopinath RS, Srikumaran S, J Gen Virol 2004 85 Pt 2 349 353 10.1099/vir.0.19563-0 14769892 (Pubitemid 38262569)
8. A single-nucleotide polymorphism in a herpesvirus DNA polymerase is sufficient to cause lethal neurological disease. Van de Walle GR, Goupil R, Wishon C, Damiani A, Perkins GA, Osterrieder N, J Infect Dis 2009 200 1 20 25 10.1086/599316 19456260
9. Herpesvirus interference with virus-specific antibodies: bridging antibodies, internalizing antibodies, and hiding from antibodies. Favoreel HW, Van Minnebruggen G, Van de Walle GR, Ficinska J, Nauwynck HJ, Vet Microbiol 2006 113 3-4 257 263 10.1016/j.vetmic.2005.11.003 16326036 (Pubitemid 43326224)
10. Herpesvirus chemokine-binding glycoprotein G (gG) efficiently inhibits neutrophil chemotaxis in vitro and in vivo. Van de Walle GR, May ML, Sukhumavasi W, von Einem J, Osterrieder N, J Immunol 2007 179 6 4161 4169 17785855
11. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Koppers-Lalic D, Reits EA, Ressing ME, Lipinska AD, Abele R, Koch J, Marcondes Rezende M, Admiraal P, van Leeuwen D, Bienkowska-Szewczyk K, Mettenleiter TC, Rijsewijk FA, Tampé R, Neefjes J, Wiertz EJ, Proc Natl Acad Sci USA 2005 102 14 5144 5149 10.1073/pnas.0501463102 15793001
12. Immune escape of equine herpesvirus 1 and other herpesviruses of veterinary importance. van der Meulen KM, Favoreel HW, Pensaert MB, Nauwynck HJ, Vet Immunol Immunopathol 2006 111 1-2 31 40 10.1016/j.vetimm.2006.01.006 16472872
13. Analysis of Equid Herpesvirus 1 Strain Variation Reveals a Point Mutation of the DNA Polymerase Strongly Associated with Neuropathogenic versus Nonneuropathogenic Disease Outbreaks. Nugent J, Birch-Machin I, Smith KC, Mumford JA, Swann Z, Newton JR, Bowden RJ, Allen GP, Davis-Poynter N, J Virol 2006 80 8 4047 4060 10.1128/JVI.80.8.4047-4060.2006 16571821
14. A point mutation in a herpesvirus polymerase determines neuropathogenicity. Goodman LB, Loregian A, Perkins GA, Nugent J, Buckles EL, Mercorelli B, Kydd JH, Palu G, Smith KC, Osterrieder N, Davis-Poynter N, PLoS Pathogens 2007 3 11 160 10.1371/journal.ppat.0030160 17997600 (Pubitemid 350291596)
15. Equine herpesvirus type 1 modified live virus vaccines: quo vaditis? Rosas CT, Goodman LB, von Einem J, Osterrieder N, Expert Rev Vaccines 2006 5 1 119 131 10.1586/14760584.5.1.119 16451114
16. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus. Van de Walle GR, May MA, Peters ST, Metzger SM, Rosas CT, Osterrieder N, Vaccine 2010 28 4 1048 1055 10.1016/j.vaccine.2009.10.123 19897066
17. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Goodman LB, Wagner B, Flaminio MJBF, Sussman KH, Metzger SM, Holland R, Osterrieder N, Vaccine 2006 24 17 3636 3645 10.1016/j.vaccine.2006.01.062 16513225
18. Control of EHV-1 viremia and nasal shedding by commercial vaccines. Goehring LS, Wagner B, Bigbie R, Hussey SB, Rao S, Morley PS, Lunn DP, Vaccine 2010 28 32 5203 5211 10.1016/j.vaccine.2010.05.065 20538091
19. The equine herpesvirus 1 IR6 protein that colocalizes with nuclear lamins is involved in nucleocapsid egress and migrates from cell to cell independently of virus infection. Osterrieder N, Neubauer A, Brandmueller C, Kaaden OR, O'Callaghan DJ, J Virol 1998 72 12 9806 9817 9811716 (Pubitemid 28520846)
20. The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence. Osterrieder N, Neubauer A, Brandmueller C, Kaaden OR, O'Callaghan DJ, Virology 1996 226 2 243 251 10.1006/viro.1996.0652 8955044 (Pubitemid 27025804)
21. The equine herpesvirus 1 IR6 protein is nonessential for virus growth in vitro and modified by serial virus passage in cell culture. Osterrieder N, Holden VR, Brandmueller C, Neubauer A, Kaaden OR, O'Callaghan DJ, Virology 1996 217 2 442 451 10.1006/viro.1996.0138 8610435 (Pubitemid 26121171)
22. Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread. Rudolph J, Osterrieder N, Virology 2002 293 2 356 367 10.1006/viro.2001.1277 11886256
23. The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11. von Einem J, Wellington J, Whalley JM, Osterrieder K, O'Callaghan DJ, Osterrieder N, J Virol 2004 78 6 3003 3013 10.1128/JVI.78.6.3003-3013.2004 14990719 (Pubitemid 38314358)
24. In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1) mutants devoid of the viral chemokine-binding glycoprotein G (gG). von Einem J, Smith PM, Van de Walle GR, O'Callaghan DJ, Osterrieder N, Virology 2007 362 1 151 162 10.1016/j.virol.2006.12.008 17250864 (Pubitemid 46617683)
25. Vaccination of ponies with the IE gene of EHV-1 in a recombinant modified live vaccinia vector protects against clinical and virological disease. Soboll G, Breathnach CC, Kydd JH, Hussey SB, Mealey RM, Lunn DP, Vet Immunol Immunopathol 2010 135 1-2 108 117 10.1016/j.vetimm.2009.11.009 20018383
26. Detection and quantification of equine herpesvirus-1 viremia and nasal shedding by real-time polymerase chain reaction. Hussey SB, Clark R, Lunn KF, Breathnach C, Soboll G, Whalley JM, Lunn DP, J Vet Diagn Invest 2006 18 4 335 342 16921871 (Pubitemid 44181971)
27. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Breathnach CC, Rudersdorf R, Lunn DP, Vet Immunol Immunopathol 2004 98 3-4 127 136 10.1016/j.vetimm.2003.11.004 15010222 (Pubitemid 38317026)
28. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies. Soboll G, Hussey SB, Whalley JM, Allen GP, Koen MT, Santucci N, Fraser DG, Macklin MD, Swain WF, Lunn DP, Vet Immunol Immunopathol 2006 111 1-2 81 95 10.1016/j.vetimm.2006.01.011 16549215
29. Equine Immunology Resource Page. http://www.ca.uky.edu/Gluck/HorohovDW- EIRClonedCytokines.asp
30. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 4 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
31. Luminex Technology. http://www.luminexcorp.com
32. Development of a bead-based multiplex assay for simultaneous quantification of cytokines in horses. Wagner B, Freer H, Vet Immunol Immunopathol 2009 127 3-4 242 248 10.1016/j.vetimm.2008.10.313 19027964
33. Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995. Lunn DP, Holmes MA, Antczak DF, Agerwal N, Baker J, Bendali-Ahcene S, Blanchard-Channell M, Byrne KM, Cannizzo K, Davis W, Hamilton MJ, Hannant D, Kondo T, Kydd JH, Monier MC, Moore PF, O'Neil T, Schram BR, Sheoran A, Stott JL, Sugiura T, Vagnoni KE, Vet Immunol Immunopathol 1998 62 2 101 143 10.1016/S0165-2427(97)00160-8 9638857 (Pubitemid 28222407)
34. Cytokine profiles and long-term virus-specific antibodies following immunization of CBA mice with equine herpesvirus 1 and viral glycoprotein D. Zhang Y, Smith PM, Frampton AR, Osterrieder N, Jennings SR, O'Callaghan DJ, Viral Immunol 2003 16 3 307 320 10.1089/088282403322396118 14583146 (Pubitemid 37229543)
35. Transforming growth factor-beta induced by live or ultraviolet- inactivated equid herpes virus type-1 mediates immunosuppression in the horse. Charan S, Palmer K, Chester P, Mire-Sluis AR, Meager A, Edington N, Immunology 1997 90 4 586 591 10.1046/j.1365-2567.1997.00202.x 9176113 (Pubitemid 27142183)
36. Frequency and phenotype of EHV-1 specific, IFN-gamma synthesising lymphocytes in ponies: the effects of age, pregnancy and infection. Paillot R, Daly JM, Luce R, Montesso F, Davis-Poynter N, Hannant D, Kydd JH, Dev Comp Immunol 2007 31 2 202 214 10.1016/j.dci.2006.05.010 16824599 (Pubitemid 44436569)
37. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. Paillot R, Daly JM, Juillard V, Minke JM, Hannant D, Kydd JH, Vaccine 2005 23 36 4541 4551 10.1016/j.vaccine.2005.03.048 15913852 (Pubitemid 40967983)
38. Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte responses in horses infected with equine herpesvirus 1. Allen GP, Yeargan M, Costa LR, Cross R, J Virol 1995 69 606 612 7983765 (Pubitemid 24378849)
39. Cytokine responses to EHV-1 infection in immune and non-immune ponies. Coombs DK, Patton T, Kohler AK, Soboll G, Breathnach C, Townsend HGG, Lunn DP, Vet Immunol Immunopathol 2006 111 1-2 109 116 10.1016/j.vetimm.2006.01.013 16473413
40. Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain. Hannant D, Jessett DM, O'Neill T, Dolby CA, Cook RF, Mumford JA, Res Vet Sci 1993 54 299 305 10.1016/0034- 5288(93)90126-Z 8393207 (Pubitemid 23171881)
41. Cell-mediated immunity evaluation in foals infected with virulent equine herpesvirus-1 by multi-parameter flow cytometry. Platt R, Sponseller BA, Chiang YW, Roth JA, Vet Immunol Immunopathol 2010 135 3-4 275 281 10.1016/j.vetimm. 2009.12.010 20116862